Cite
HARVARD Citation
Takashina, T. et al. (n.d.). 3071 A phase II study of carboplatin (Cb), pemetrexed (PEM), and bevacizumab (Bev) followed by Bev and erlotinib (Erl) maintenance for non-squamous non-small cell lung cancer (NS-NSCLC) with wild-type (WT) EGFR. European journal of cancer. pp. S620-. [Online].